DREAM11 S’APPUIE SUR LES DONNÉES DE VOLT ACTIVE DATA POUR ENGAGER 130 MILLIONS D’UTILISATEURS DANS L’IPL 2022

La plus grande plateforme de sports de fantaisie au monde a annoncé l’expansion récente de son partenariat avec Volt Active Data sur la lancée d’un succès mesurable.

BEDFORD, Massachusetts, 28 avril 2022 /PRNewswire/ — Volt Active Data, la seule plateforme de données d’entreprise conçue pour répondre aux exigences en temps réel des sociétés de jeux de grande envergure et des sociétés de technologie à fortes transactions actuelles, a annoncé aujourd’hui que Dream11, la plus grande plateforme de sports fictifs du monde, a étendu son contrat avec Volt.

Volt Active Data Logo

Dream11 compte plus de 130 millions d’utilisateurs actifs et est déjà prête à gérer en production plus de 10 millions d’utilisateurs simultanés aux heures de pointe. Dream11 a initialement commencé avec Volt lors de la saison 2018 de l’IPL, et après avoir constaté le succès de la technologie (en partie grâce à la faible latence, au débit élevé et à l’assurance de disponibilité que fournit la plateforme Volt), elle a décidé d’approfondir sa relation avec Volt et d’élargir son utilisation de la plateforme Volt Active Data.

« C’est une situation gagnant-gagnant pour Dream11 et Volt », a déclaré David Flower, PDG de Volt Active Data. « L’expansion représente non seulement une autre validation de la plateforme Volt Active Data en tant que leader de la technologie des données en temps réel, mais elle change également la donne pour Dream11, car cela va essentiellement assurer l’avenir de leur plateforme pour la croissance explosive qu’ils connaissent et continueront de connaître ».

Volt fournit la précision, la fiabilité et les performances exigées par les millions de fans de sport qui cherchent à participer à des concours fantaisistes pendant l’IPL. Que ce soit entre amis ou parmi un million d’autres fans en compétition pour montrer leurs compétences et leurs connaissances du cricket, la faible latence de Volt, même en cas d’énormes pics de trafic (juste après le lancement du jeu), permet à Dream11 d’offrir la meilleure expérience de fantaisie aux fans et de devenir le choix numéro un en Inde pour les sports de fantaisie.

« La saison 2022 de l’IPL promettant d’établir de nouveaux records dans tous les domaines, nous savions que c’était le moment idéal pour intensifier notre relation stratégique avec l’équipe de Volt Active Data », a déclaré Amit Sharma, directeur technique de Dream11. « Chez Dream11, une excellente expérience utilisateur, une approche axée sur les données et une technologie de pointe sont toujours au cœur de nos préoccupations. Le défi du modèle de données auquel nous sommes confrontés pendant l’IPL est très nuancé et Volt est la seule plateforme que nous avons trouvée qui peut nous aider à surmonter ces défis techniques ».

À propos de Volt Active Data

Volt Active Data permet aux applications d’entreprise d’ingérer, de traiter et d’agir sur les données en quelques millisecondes pour exploiter de nouvelles sources de revenus et prévenir les pertes de revenus. Avec des clients de premier plan dans les télécommunications, la finance, les jeux et bien d’autres secteurs verticaux, la plateforme Volt est positionnée de manière unique pour être la technologie de référence de toute entreprise cherchant à tirer pleinement parti de la 5G, de l’IoT et de tout ce qui suivra. En savoir plus sur voltactivedata.com.

Logo – https://mma.prnewswire.com/media/1805076/Volt_Active_Data_Logo.jpg

Disease Outbreak News: Cholera – Malawi (27 April 2022)

Outbreak at a glance

The Ministry of Health declared a cholera outbreak in Malawi on 3 March 2022, following laboratory confirmation of a case in in the country. A second case was detected in on 7 March. As of 26 April, 78 cholera cases and four deaths have been reported, of which 97% (76 cases) have been reported from Nsanje district. Several response measures have been implemented including delivery of cholera kits, mapping of hotspot districts.

Description of the outbreak

On 3 March 2022, the Ministry of Health Malawi declared a cholera outbreak in the country, following confirmation of a case in a 57-year-old male, from Machinga district, in Southern Malawi. On 28 February, the case developed watery diarrhoea and visited Machinga hospital where cholera was confirmed on 2 March. Samples from the patient tested positive by culture and Vibrio cholerae O1, serotype Inaba was isolated. The case had a history of travel to two cities – Blantyre and Machinga — prior to being admitted to the district hospital. Although an epidemiological investigation was carried out, the source of the infection was not identified.

On 7 March 2022, a second case was identified in a 11-year-old boy at a local health centre from Nsanje district, Malawi. The case was displaced to Mozambique following floods caused by the tropical storm Ana and cyclone Gombe and returned to Malawi while symptomatic.

As of 26 April 2022, a total of 78 cholera cases with four deaths (case fatality ratio: 5.1%) have been reported from Nsanje (76 cases; four deaths) and Machinga (2 cases) districts (Figures 1 and 2). Of the 78 cases, 13 have been confirmed by culture, and 20 tested positive by rapid diagnostic test (RDT). The age of the cases range between 2 and 57 years, with the 5 to 14 years age group being the most affected.

The Southern region of Malawi was severely affected by the tropical storm Ana and cyclone Gombe that caused torrential rains and floods between late January and February 2022. The displaced populations remained with no access to safe drinking water and sanitation facilities and thus, at risk of widespread disease outbreaks including cholera.

Epidemiology of cholera

Cholera is an acute enteric infection caused by ingesting the bacteria Vibrio cholerae present in contaminated water or food. It is mainly linked to insufficient access to safe drinking water and inadequate sanitation. It is an extremely virulent disease that can cause severe acute watery diarrhoea resulting in high morbidity and mortality, and can spread rapidly, depending on the frequency of exposure, the exposed population and the setting. Cholera affects both children and adults and can be fatal if untreated.

The incubation period is between 12 hours and 5 days after ingestion of contaminated food or water. Most people infected with V. cholerae do not develop any symptoms, although the bacteria are present in their faeces for 1-10 days after infection and are shed back into the environment, potentially infecting other people. Among people who develop symptoms, the majority have mild or moderate symptoms, while a minority develop acute watery diarrhoea with severe dehydration. Cholera is an easily treatable disease. Most people can be treated successfully through prompt administration of oral rehydration solution (ORS).

Cholera can be endemic or epidemic. A cholera-endemic area is an area where confirmed cholera cases were detected during the last 3 years with evidence of local transmission (cases are not imported from elsewhere). A cholera epidemic can occur in both endemic countries and in non-endemic countries.

The consequences of a humanitarian crisis – such as disruption of water and sanitation systems, or the displacement of populations to inadequate and overcrowded camps – can increase the risk of cholera transmission, should the bacteria be present or introduced. Uninfected dead bodies have never been reported as the source of epidemics.

A multifaceted approach including a combination of surveillance, water, sanitation and hygiene, social mobilization, treatment, and oral cholera vaccines is essential to control cholera outbreaks and to reduce deaths.

Public health response

WHO, in coordination with partners, is supporting the implementation of the National Cholera Response Plan in Malawi.

Other specific actions undertaken include:

• National and district level emergency operation centres (EOCs) were activated and currently coordinating the response in collaboration with other health sectors and partners.

• Initial mapping of the high risk/ hotspot districts was conducted in late February 2022, after the landfall of tropical storm, and an update was conducted on 25 March 2022.

• The Ministry of Health and WHO jointly completed field supervision including risk and needs assessments. A comprehensive report is being prepared.

• Four data managers and three public health officers were engaged and deployed to the affected districts for data management.

• Cholera preparedness training was conducted from 21 to 22 April 2022 in Nsanje district.

• WHO has provided cholera kits and other supplies to the affected districts.

• A request for an oral cholera vaccine (OCV) submitted to the International Coordination Group (ICG) for 3.9 million doses of vaccines targeting eight high risk districts was approved. The country has received more than 1.9 million doses of OCV for the first round of the campaign planned for early May 2022.

• Supplies for case management and laboratory confirmation of cholera are pre-positioned in health facilities and the district laboratory. Case management has been strengthened through the establishment of treatment structures and the provision of equipment. Two cholera treatment centres have been established in Nsanje district.

• The collection and analysis of stool samples for confirmation at the district public health laboratory continues. A total of 13 samples were confirmed by laboratory analysis (culture) as of 26 April 2022.

• Efforts to collaborate with the Mozambique team are underway through the regional coordination in the East, Central and South Africa.

WHO risk assessment

Cholera is endemic in Malawi with seasonal outbreaks being reported from 1998 to 2020. The Southern region, which shares border with Mozambique, remains the hotspot of the recurrent cholera outbreaks. The detection of cholera cases is concerning as Malawi has low population immunity in the districts reporting confirmed cases.

The main factors attributed to the initiation and ongoing spread of the cholera epidemics in the two affected districts include:

• Tropical storm and floods

• Inadequate hygiene and sanitation

• Limited access to safe drinking water and personal hygiene practices

• Open defecation

• Delay in seeking care

Other identified challenges from Nsanje and neighbouring at-risk districts (Balaka and Chikwawa) include poor capacity for sample collection, transportation, and diagnosis in the affected areas mainly due to the difficult access following floods.

Additionally, Malawi shares international borders with Mozambique, and there is frequent and substantial cross-border population movement, including people displaced following the floods caused by the tropical cyclone. This poses a risk of cross-border transmission of cholera.

Close monitoring of the situation with active cross-border coordination and information sharing remains crucial.

WHO advice

Prevention and control: WHO recommends improving access to clean water and sanitation, good waste management, food safety practices and hygienic practices to prevent the transmission of cholera. OCV should be used in combination with improvements in water and sanitation to control cholera outbreaks and for prevention in areas known to be at-high risk for cholera.

Surveillance: Strengthening surveillance, particularly at the community level, is advised. There is a need to ensure that countries are ready to quickly detect and respond to this cholera outbreak to reduce the risk of spread to new areas. As the outbreak is occurring in border areas where there is significant cross border movement, WHO encourages the respective countries to ensure cooperation and regular information sharing.

Case management: Appropriate case management, including improving access to care, should be implemented in outbreak-affected areas to reduce mortality.

International travel and Trade: WHO does not recommend any restrictions on travel and trade to and from Malawi.

Source: World Health Organization

UNICEF Malawi Humanitarian Situation Report, 13-28 April 2022

Floods – Humanitarian Situation in numbers, 28 April 2022

79 Cholera cases with 4 deaths

More than 995,000 people affected by floods including 130,000 under-five children need humanitarian assistance

Over 190,000 people displaced by floods

1 case of Polio

Highlights

• 63,006 children (32,763 girls 30,243 boys) have undergone nutrition screening bringing the total reach to 132,822 children (68,536 male 64,286 female).

• 40,000 cholera patients will benefit from 3 types of health kits which UNICEF has provided to four flood-affected districts (Nsanje, Chikwawa, Mulanje and Phalombe). Each kit contains a range of prepacked supplies including medicines like albendazole and oral rehydration salts and infection prevention and protective equipment.

• 5,366 people were reached with emergency sanitation interventions in displacement sites across affected districts.

• 1,812 households have been reached with key messages and counselling on WASH, Nutrition, Vitamin A, Exclusive Breastfeeding, Complementary Feeding, COVID-19 prevention, anti-natal care and benefits of iron and Folic Acid to pregnant women and adolescent girls.

Situation Overview

A series of flooding events including Tropical Storms Ana and Gombe and sporadic flooding occurrences that hit the country over the period of January to March 2022 led to over 190,000 people displaced and left seeking shelter in displacement sites. These people have now started moving back to their places of origin while others are planning to resettle in newly identified areas that they consider to be less prone to flooding. The Government facilitated discussions on a harmonised return package to be provided by humanitarian actors to the affected people as a starter pack to rebuild their lives. Humanitarian actors are mobilizing resources to provide the much-needed return package to the people as they go through the transition.

Since the declaration of a Cholera outbreak in Malawi on 3 March 2022, a total of 79 cases and four deaths have been registered as of 25 April 2022 representing a case fatality rate of five per cent. COVID-19 cases and deaths continue to drop. This reporting period has seen a drop in new infections by 46 per cent, and hospital admissions reduced by 76 per cent from the previous reporting period. The positivity rate lingers at around one per cent. As of 26 April, three cases were hospitalized. Since the beginning of the pandemic, 85,752 cases and 2,633 deaths have been registered. COVID vaccination status presently stands at 1,107,875 fully immunized people from 908,688 reported in the previous report. This is about 10 per cent of the targeted reach. In addition, close to 277,000 AstraZeneca vaccines that were to expire in May 2022 have all been used. The success was attributed to the strong collaboration between the Ministry of Health and partners, during the “finish-a-vial” campaign to scale up coverage.

No additional Wild Polio Virus (WPV) case has been registered since the index was reported in February 2022. The second of four planned rounds of vaccination campaigns against wild poliovirus Type-1 started on 25 April 2022. More than 11 million doses are being administered to more than 2.9 million children under 5 years in the four-round vaccination drive in Malawi after the country declared an outbreak on 17 February 2022 – the first such case in the country in 30 years, and the first in Africa since the region was certified free of indigenous wild poliovirus in 2020. This second phase of the campaign targets children under 5 in Malawi, as well as neighbouring Mozambique, Tanzania and Zambia. Two subsequent rounds are set for June and July, with the first having already taken place in April. Cumulatively, the target is to reach over 23 million children with more than 80 million doses of the bivalent Oral Polio Vaccine recommended by the World Health Organization (WHO) for wild poliovirus (type 1). So far in 2022, 92 Acute cases of Flaccid Paralysis (AFP) have been reported in Malawi compared to 25 cases by the same time last year. The high number of AFP reports could be attributed to good surveillance and increased reporting as a result of the ongoing OPV campaigns.

The number of children admitted for severe acute malnutrition (SAM) treatment increased mainly in Chikwawa by 60 per cent from 599 in March 2021 to 959 in March 2022. Overall, there is a 49 per cent increase in SAM admissions from 3,953 in March 2021 to 5,904 in March 2022. Data for April 2022 is being compiled but indications from field observations are that the situation is continuing to deteriorate.

Source: UN Children’s Fund

Vaccine-Preventable Diseases Surging in Africa Due to COVID-19 Disruptions

The World Health Organization warns that vaccine-preventable diseases are spreading across the African continent because routine immunizations against killer diseases have been disrupted by the COVID-19 pandemic.

Tens of millions of people have missed out on routine immunization services. That not only puts their lives at risk from potentially deadly diseases but creates an environment in which killer diseases can thrive and spread.

Benido Impouma, director for communicable and noncommunicable diseases in the World Health Organization’s regional office for Africa, said the pandemic has put a huge strain on health systems. It has impaired routine immunization services in many African countries and forced the suspension of vaccination drives.

Over the past year, he said, outbreaks of vaccine-preventable diseases have increased across the continent.

“For instance, between January and March of this year, around 17,000 cases of measles were recorded. This is a 400 percent increase compared with the same period last year,” Impouma said. “Twenty-four countries in our region confirmed outbreaks of a variant of polio last year, which is four times more than in 2020.”

He noted that outbreaks of other vaccine-preventable diseases, such as yellow fever, also are surging.

The World Health Organization and UNICEF recently issued a report warning of a heightened risk of vaccine-preventable diseases. They attribute it in large part to increasing inequalities in access to vaccines due to pandemic-related disruptions.

They expressed particular concern about a worldwide spike in measles cases, which have increased by 79 percent in the first two months of this year. They noted that most cases were reported in Africa and in eastern Mediterranean regions.

WHO is working to improve immunization coverage and protection for children, Impouma said, adding that WHO and its partners are supporting African countries to carry out catch-up routine vaccination campaigns.

“More than 30 African countries implemented at least one routine catch-up immunization campaign in the second half of last year,” he said. “And this year, countries are showing progress, with measles and yellow fever campaigns starting again. Central African Republic, Chad, Equatorial Guinea, Ethiopia, Nigeria, Somalia and South Sudan have reinstated measles campaigns, which is good news.”

However, COVID-19 news is not as promising. WHO said that this week new COVID-19 cases and deaths on the continent have increased for the first time after a decline of more than two months for cases and one month for deaths.

The latest recorded figures put the number of cases at 11.6 million, including nearly 253,000 deaths.

Source: Voice of America

Moderna Seeks to Be First With COVID Shots for Littlest Kids

Moderna said two kid doses were about 40% to 50% effective at preventing symptomatic COVID-19, not a home run, but for many parents, any protection would be better than none.

That effectiveness is “less than optimal. We were hoping for better efficacy, but this is a first step,” said Dr. Nimmi Rajagopal of Cook County Health in Chicago. She’s anxiously awaiting vaccinations for her youngest patients and her own 3-year-old son, who’s ready to enter preschool.

“It gives me such peace of mind to know that hopefully by fall I’ll get him in school and he’ll be fully vaccinated,” she said.

Now, only children age 5 or older can be vaccinated in the U.S., using rival Pfizer’s vaccine, leaving 18 million younger tots unprotected.

Moderna’s vaccine isn’t the only one in the race. Pfizer is soon expected to announce whether three of its even smaller-dose shots work for the littlest kids, months after the disappointing discovery that two doses weren’t quite strong enough.

Evaluation process

Whether it’s one company’s shots or both, FDA vaccine chief Dr. Peter Marks said the agency will “move quickly without sacrificing our standards” in deciding if tot-sized doses are safe and effective.

While questions are swirling about what’s taking so long, Marks pointedly told lawmakers earlier this week that the FDA can’t evaluate a product until a manufacturer completes its application. In a statement Thursday, the FDA said that it would schedule a meeting to publicly debate Moderna’s evidence with its independent scientific advisers, but that the company still must submit some additional data. Moderna expects to do so next week.

“It’s critically important that we have the proper evaluation so that parents will have trust in any vaccines that we authorize,” Marks told a Senate committee.

If the FDA clears vaccinations for the littlest, the Centers for Disease Control and Prevention would next have to recommend who needs them — all tots or just those at higher risk from COVID-19.

“It’s very important to get the youngest children vaccinated,” but “moving quickly doesn’t mean moving sloppily,” said Dr. Philip Landrigan, a pediatrician and public health expert at Boston College. The FDA must “see if it’s safe. They need to see if it’s effective. And they need to do so swiftly. But they won’t cut corners.”

Many parents are desperate for whichever vaccine gets to the scientific finish line first.

“We’ve been kind of left behind as everybody else moves on,” said Meagan Dunphy-Daly, a Duke University marine biologist whose 6-year-old daughter is vaccinated and whose 3-year-old and 18-month-old sons are part of Pfizer’s trial.

The family continues to mask and take other precautions until it’s clear if the boys got real vaccine or dummy shots. If it turns out they weren’t protected in the Pfizer study and Moderna’s shots are cleared first, Dunphy-Daly said she’d seek them for her sons.

“I will feel such a sense of relief when I know my boys are vaccinated and that the risk of them getting a serious infection is so low,” she said.

The FDA will face some complex questions.

In a study of 6,700 kids ages 6 months through 5 years, two Moderna shots — each a quarter of the regular dose — triggered high levels of virus-fighting antibodies, the same amount proven to protect young adults, said Burton of Moderna. There were no serious side effects, and the shots triggered fewer high fevers than other routine vaccinations.

But depending on how researchers measured, the vaccine proved at best about 51% effective at preventing COVID-19 cases in babies and toddlers and about 37% effective in the 2- to 5-year-olds. Burton blamed the omicron variant’s ability to partially evade vaccine immunity, noting that unboosted adults showed similarly less effectiveness against milder omicron infections. While no children became severely ill during the study, he said high antibody levels are a proxy for protection against more serious illness — and the company will test a child booster dose.

“That’s not totally out of the realm of what we would have expected,” said Dr. Bill Muller of Northwestern University, who helped with Moderna’s child studies. “Down the road I would anticipate it’s going to be a three-shot series.”

Another issue: So far in the U.S., Moderna’s vaccine is restricted to adults. Other countries have expanded the shot to kids as young as 6. But while Moderna has filed FDA applications for older kids, too, the FDA hasn’t ruled on them. Months ago, the agency cited concern about a rare side effect, heart inflammation, in teen boys, a concern that hasn’t been reported in much younger children.

It’s not clear if the FDA will consider Moderna’s vaccine for children of all ages now or focus first on the littlest. But Muller already has had lots of parents ask why shots were being tested in tots before older kids were vaccinated — and says pediatricians and pharmacists must be ready with answers.

Burton said safety data from millions of older children given Moderna vaccinations abroad should help reassure parents.

While COVID-19 generally isn’t as dangerous in youngsters as adults, some do become severely ill or even die. About 475 children younger than 5 have died from COVID-19 since the pandemic’s start, according to the CDC, and child hospitalizations soared at omicron’s peak.

Yet it’s not clear how many parents intend to vaccinate the youngest kids. Less than a third of children ages 5 to 11 have had two vaccinations, and 58% of those ages 12 to 17.

Source: Voice of America

African golf confederation recognizes Angola’s good organization

Luanda – The secretary general of the African Golf Confederation, Hugh Mortimer, considered the organization of the African Championship that ended this Wednesday in Angola to be excellent, even with covid-19 pandemic issues, which affected world’s economy.

The official told ANGOP that Angola had accepted the challenge of hosting the event and did it with great skill, adding that, despite being fourth in the ranking, the country has shown that can compete on an equal footing with any opponent.

The Namibian recognizes that Angolan golf is under development, but will seek to use his influence with the sport’s top bodies to receive support to invest in massification.

He recalled that Angola has been an active member of Region V since 2019 and the problems it faces are no different from other countries that also lack great support for the development of the sport.

Source: Seychelles News Agency